Balchem Corp. Q1 2010 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients for food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The company operates through three segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $59,903 | $52,986 |
| Gross Margin | $17,414 (29.1%) | $16,298 (30.8%) |
| Operating Income | $10,494 | $9,310 |
| Net Earnings | $7,029 | $6,098 |
| Diluted EPS | $0.24 | $0.21 |
| Cash from Operations | $9,697 | $18,502 |
| Cash & Equivalents (End) | $51,361 | $18,553 |
| Total Debt (Current) | $6,007 | $6,783 |
| Working Capital | $67,986 | $59,197 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.1% year-over-year, driven by volume growth across all segments. The Animal Nutrition & Health segment saw a 12.2% increase, while Food, Pharma & Nutrition grew 20.0%.
- Margin Compression: Gross margin percentage declined from 30.8% to 29.1%. Management attributes this to higher petro-chemical based raw material costs and an unfavorable product mix, which offset the benefits of increased sales volumes.
- Operating Expenses: Total operating expenses decreased slightly (1.0%) to $6,920, primarily due to lower general and administrative expenses, despite increased R&D spending ($868 vs. $808).
- Cash Flow: Operating cash flow decreased significantly to $9,697 from $18,502 in the prior year, largely due to increases in accounts receivable and inventory levels.
- Debt Reduction: The company paid off its $29,000 Term Loan in full. Remaining debt consists of a European Term Loan with an outstanding balance of $6,007.
Outlook, Risks, and Management Commentary
- Outlook: Management continues to focus on volume growth in export markets and new product launches. The company is actively pursuing acquisition candidates and expects operations to generate sufficient cash flow for working capital and capital investments.
- Cost Pressures: The primary risk to margins remains the volatility of petro-chemical raw material costs, which impacts the Specialty Products and Animal Nutrition segments.
- Foreign Exchange: The company recorded $119 in other income due to favorable foreign currency fluctuations. It remains exposed to market risks regarding foreign currency rates and commodity prices.
- Contingencies: The company is involved in ongoing environmental monitoring at its Slate Hill, NY site (costs <$5/year) and maintains capped areas at its Verona, MO facility (indemnified by prior owners). Management believes these matters will not materially affect financial position.
- Dividends: Dividends paid increased to $3,091 in Q1 2010 compared to $2,008 in Q1 2009.
Investor Verification Checklist
- Raw Material Costs: Verify the trajectory of petro-chemical input costs and the company's ability to pass these costs to customers to protect gross margins.
- Working Capital Efficiency: Investigate the drivers behind the significant increase in accounts receivable and inventory, which reduced operating cash flow despite higher earnings.
- Debt Covenants: Confirm continued compliance with loan covenants (Current Ratio, Funded Debt Ratio, Fixed Charge Coverage Ratio) as the company pursues potential acquisitions.
- Segment Mix: Monitor the product mix within the Specialty Products segment, which saw a 5.2% decline in gross margin percentage.
- Acquisition Pipeline: Assess the status of the "actively pursued" acquisition candidates mentioned in the liquidity section.